Efficacy of Remdesivir and Neutralizing Monoclonal Antibodies in Monotherapy or Combination Therapy in Reducing the Risk of Disease Progression in Elderly or Immunocompromised Hosts Hospitalized for COVID-19: A Single Center Retrospective Study.
Davide Fiore BavaroLucia DiellaAlessandra BelatiGiuliana MetrangoloLaura De SantisVito SpadaMichele CamporealeAngelo DargenioGaetano BrindicciFlavia BalenaDeborah FiordelisiFabio SignorileGiacomo LosetoCrescenza PasciollaCarla MinoiaImmacolata AttolicoTommasina PerroneSimona SimoneMaria RendinaNicoletta GiovineFrancesco Di GennaroPellegrino MustoAttilio GuariniAlfredo Di LeoLoreto GesualdoMaria Dell'AeraAnnalisa SaracinoPublished in: Viruses (2023)
REM and mAbs may reduce the risk of COVID-19 progression in hospitalized patients. Importantly, in immunocompromised hosts, the combination of mAbs and REM may be beneficial.